Metabonomics study of obesity hyperuricemia based on GC-MS.

doi:10.3877/cma.j.issn.2095-9605.2020.04.003

Abstract

Abstract:

Objective

To find and identify the common metabolites of patients whom obesity with hyperuricemia, further investigate the reasons for hyperuricemia that caused by obesity.

Methods

The metabolic profile of urine samples from patients whom hyperuricemia with obesity, simple obesity and healthy subjects were analyzed by gas chromatography-mass spectrometry (GC-MS); Further, the MPP was used to analyze the original data from above mentioned three different groups, that in order to obtain the urine differential metabolites.

Results

The six differential metabolites that includes, 2,3-dihydroxybutanoic acid, erythritol, stearic acid, 2,3,4-trihydroxybutyric acid, D-gluconic acid and 1-monopalmitin were screened and identified by mass spectrometry and database search.

Conclusions

These six differential metabolites may be the main cause of hyperuricemia by obesity.

Key words: Hyperuricemia, Obesity, Metabonomics

Aipire Aliyeguli, Abudureyimu Kelimu, Yongbin Ma, Aili Aikebaier. Metabonomics study of obesity hyperuricemia based on GC-MS.[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2020, 06(04): 223-226.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2020.04.003

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2020/V06/I04/223

Figures/Tables 2

References 20

[1]	韦桂宁, 苏启表, 何飞, 等. 拟黑多刺蚁乙醇提取物中降低小鼠血清尿酸水平活性部位的筛选与化学成分分析[J]. 中国药理学与毒理学杂志, 2013, 27(004): 673-677.
[2]	关文锦. 高尿酸血症高危人群检测结果分析[J].国际检验医学杂志, 2012, 33(16): 1978-1980.
[3]	郭德凯, 朱江帆. 肥胖症、高尿酸血症和代谢手术相关性的研究进展[J/CD].中华肥胖与代谢病电子杂志, 2017, 3(1): 46-48.
[4]	罗恒,徐红. 别嘌呤醇干预高尿酸血症模型大鼠的代谢组学特征[J/CD].浙江临床医学, 2017, 19(012): 2182-2184.
[5]	刘丹丹, 崔雯霞, 胡云, 等. 高尿酸血症对慢性肾脏病影响的研究进展[J]. 中国临床研究, 2020, 33(1): 120-123.
[6]	Yang Y, Tian J, Zeng C, et al. Relationship between hyperuricemia and risk of coronary heart disease in a middle-aged and elderly Chinese population[J]. J Int Med Res, 2017, 45(1): 254-260.
[7]	王长磊, 孔纯玉, 戚务芳, 等. 类风湿关节炎患者血清镁浓度与代谢综合征糖尿病、高血压、高尿酸血症之间的关系[J]. 中华风湿病学杂志, 2020, 24(06): 403-408.
[8]	闻志楠，陈欣，刘迎午, 等. 不同程度冠状动脉病变冠心病患者的代谢组学特点及诊断价值[J]. 中国动脉硬化杂志, 2020, 28(2): 134-140.
[9]	刘亚琪, 王中华, 何秉淑, 等. 基于液相色谱-质谱技术的肾脏代谢组学分析方法研究[J]. 分析测试学报, 2020, 39(1): 121-127.
[10]	曾威, 罗艳, 黄可儿, 等. 广陈皮抗高脂血症的血清代谢组学研究[J]. 中药新药与临床药理, 2020, 31(1): 78-85.
[11]	金一宝, 李上富, 王珏, 等. 基于液相色谱-质谱联用的代谢组学技术研究Pokemon诱导的胞内脂代谢变化[J]. 色谱, 2020, 47(2): 21-27.
[12]	Chan ECY, Pasikanti KK, Nicholson JK. Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry[J]. Nature Protocols, 2011, 6(10): 1483-1499.
[13]	凯赛尔·艾则孜. 新疆地区健康、超重、肥胖三种人群尿液代谢组学差异分析[D]. 新疆医科大学, 2018.
[14]	Song P, Wang H, Xia W, et al. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China[J]. entific Reports, 2018, 8(1):4314.
[15]	Ricotti R, Genoni G, Giglione E, et al. High-normal estimated glomerular filtration rate and hyperuricemia positively correlate with metabolic impairment in pediatric obese patients[J]. Plos One, 2018, 13(3): e0193755.
[16]	Rathmann W, Haastert B, Icks A, et al. Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study[J]. Eur J Epidemiol, 2007, 22(7): 439-445.
[17]	Wishart DS. Metabolomics: applications to food science and nutrition research[J]. Trends in Food ence & Technology, 2008, 19(9): 482-493.
[18]	Nicholson JK, Connelly J, Lindon JC, et al. Metabonmics: a platform for studying drug toxicity and gene function[J]. Nat Rev Drug Discov, 2002, 1(2):153-161.
[19]	迪丽达尔·希力甫, 赵龙, 张向阳. 高尿酸血症大鼠模型血清代谢组学研究[J]. 科技导报, 2015, 33(016): 77-80.
[20]	武鹏, 曾富玲, 石尉宏, 等. 代谢组学在痛风及高尿酸血症研究中的应用[J]. 世界中西医结合杂志, 2019, 14(06): 878-881.

类别/组别	肥胖合并高尿酸血症组(n=22)	肥胖组(n=25)	对照组(n=57)	F值	P值
年龄（岁）	45.20±8.57	45.80±10.59	42.30±10.59	3.34	0.052
BMI（kg/m²）	41.71+6.12	36.88±5.67	21.86+1.46 ,*	9.98	0.001
腰围（cm）	119.25±14.47	119.40±17.40	83.67±3.21,*	7.29	0.004
收缩压（mmHg）	132.87±10.86	126.40±10.02	118.17±6.50*	2.60	0.095
舒张压（mmHg）	84.60±7.49	78.50±7.95	66.05±6.50,*	5.98	0.008
血糖（mmol/L）	4.46±0.59	5.26±1.27	4.14±0.65	2.81	0.08
甘油三酯（mmol/L）	1.68±0.58	2.76±02.16	1.10±0.20	2.47	0.11
游离脂肪酸（mmol/L）	0.81±0.44	0.69±0.43	0.39±0.18	0.95	0.40
HDL-C（mmol/L）	0.95±0.28	0.94±0.23	1.63±0.03,*	9.87	0.001
LDL-C（mmol/L）	3.07±0.74	2.41±0.63^#	1.90±0.36*	5.12	0.014
UA（μmol/L）	498.56±159.26	267.94±73.20^#	228.67±23.80*	12.48	0.000

类别/组别	肥胖合并高尿酸血症组(n=22)	肥胖组(n=25)	对照组(n=57)	F值	P值
年龄（岁）	45.20±8.57	45.80±10.59	42.30±10.59	3.34	0.052
BMI（kg/m²）	41.71+6.12	36.88±5.67	21.86+1.46 ,*	9.98	0.001
腰围（cm）	119.25±14.47	119.40±17.40	83.67±3.21,*	7.29	0.004
收缩压（mmHg）	132.87±10.86	126.40±10.02	118.17±6.50*	2.60	0.095
舒张压（mmHg）	84.60±7.49	78.50±7.95	66.05±6.50,*	5.98	0.008
血糖（mmol/L）	4.46±0.59	5.26±1.27	4.14±0.65	2.81	0.08
甘油三酯（mmol/L）	1.68±0.58	2.76±02.16	1.10±0.20	2.47	0.11
游离脂肪酸（mmol/L）	0.81±0.44	0.69±0.43	0.39±0.18	0.95	0.40
HDL-C（mmol/L）	0.95±0.28	0.94±0.23	1.63±0.03,*	9.87	0.001
LDL-C（mmol/L）	3.07±0.74	2.41±0.63^#	1.90±0.36*	5.12	0.014
UA（μmol/L）	498.56±159.26	267.94±73.20^#	228.67±23.80*	12.48	0.000

	Molecular Formula:	Fat+gout vs Fat	CAS Number	P值	Retention Time
2,3-二羟丁酸	C4H8O4	Up	1000099-89-5	2.11E-02	11.90978
赤藓糖醇	C4H10O4	Up	25258-02-0	4.12E-05	14.085982
硬脂酸	C18H36O2	Up	34290-52-3	1.36E-04	19.521915
2,3,4-三羟基丁酸	C4H8O5	Up	38191-88-7	3.44E-03	14.436813
D-葡萄糖酸	C6H12O7	down	1188-74-5	5.21E-16	23.988493
1-单罂粟碱，1-单棕榈酸	C19H38O4	down	18748-91-9	1.55E-05	21.135067

	Molecular Formula:	Fat+gout vs Fat	CAS Number	P值	Retention Time
2,3-二羟丁酸	C4H8O4	Up	1000099-89-5	2.11E-02	11.90978
赤藓糖醇	C4H10O4	Up	25258-02-0	4.12E-05	14.085982
硬脂酸	C18H36O2	Up	34290-52-3	1.36E-04	19.521915
2,3,4-三羟基丁酸	C4H8O5	Up	38191-88-7	3.44E-03	14.436813
D-葡萄糖酸	C6H12O7	down	1188-74-5	5.21E-16	23.988493
1-单罂粟碱，1-单棕榈酸	C19H38O4	down	18748-91-9	1.55E-05	21.135067

Please choose a citation manager

Content to export